PD1 in Sézary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?

Eur J Cancer. 2021 Oct:156 Suppl 1:S14-S15. doi: 10.1016/S0959-8049(21)00652-3.

Authors

Amandine Decroos¹, Jerome Giustiniani¹, Laura Pelletier¹, Saskia Ingen-Housz-Oro², Philippe Gaulard³, Nicolas Ortonne³

Affiliations

¹ Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France.
² Dermatology department, APHP, Henri Mondor hospital, Paris, France.
³ Research team Ortonne - NFL, IMRB, INSERM U955 Henri Mondor hospital, Paris, France; Pathology department, APHP, Henri Mondor hospital, Paris, France.

PMID: 34649644
DOI: 10.1016/S0959-8049(21)00652-3

No abstract available

Keywords: PD1; Sézary syndrome; antibody-dependent cell cytotoxicity; antibody-dependent cell phagocytosis; cell line.